MX367460B - Anticuerpos biespecificos anti-baff-anti-il-17. - Google Patents

Anticuerpos biespecificos anti-baff-anti-il-17.

Info

Publication number
MX367460B
MX367460B MX2014012692A MX2014012692A MX367460B MX 367460 B MX367460 B MX 367460B MX 2014012692 A MX2014012692 A MX 2014012692A MX 2014012692 A MX2014012692 A MX 2014012692A MX 367460 B MX367460 B MX 367460B
Authority
MX
Mexico
Prior art keywords
baff
bispecific antibodies
sjã
gren
sle
Prior art date
Application number
MX2014012692A
Other languages
English (en)
Other versions
MX2014012692A (es
Inventor
Allan Barrett
Jan Benschop Robert
Lu Jirong
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2014012692A publication Critical patent/MX2014012692A/es
Publication of MX367460B publication Critical patent/MX367460B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624Disulfide-stabilized antibody (dsFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a anticuerpos biespecíficos que específicamente enlazan el Factor de Activación de células B de la Familia TNF (BAFF) e lnterleucina-17A (lL-17) y se caracterizan porque tienen alta afinidad y fuertes propiedades neutralizantes tanto para BAFF como IL-17. Se espera que los anticuerpos biespecíficos de la invención sean útiles en el tratamiento de Nefritis Lúpica (LN), Lupus Eritematoso Sistémico (SLE), Artritis Reumatoide (RA), Psoriasis (Ps), Espondilitis Anquilosante (AS), Artritis Psoriática (PA), Síndrome de Sjögren primario (pSS), o Mieloma Múltiple (MM).
MX2014012692A 2012-04-20 2013-04-16 Anticuerpos biespecificos anti-baff-anti-il-17. MX367460B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
US201361768747P 2013-02-25 2013-02-25
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (2)

Publication Number Publication Date
MX2014012692A MX2014012692A (es) 2015-01-22
MX367460B true MX367460B (es) 2019-08-22

Family

ID=48539373

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012692A MX367460B (es) 2012-04-20 2013-04-16 Anticuerpos biespecificos anti-baff-anti-il-17.

Country Status (40)

Country Link
US (2) US9359448B2 (es)
EP (2) EP2838920B1 (es)
JP (1) JP6216772B2 (es)
KR (1) KR101673735B1 (es)
CN (1) CN104220455B (es)
AP (1) AP2014008002A0 (es)
AR (1) AR090626A1 (es)
AU (1) AU2013249546B2 (es)
BR (1) BR112014025649A2 (es)
CA (1) CA2869148C (es)
CL (1) CL2014002616A1 (es)
CO (1) CO7160039A2 (es)
CR (1) CR20140466A (es)
CY (1) CY1118824T1 (es)
DK (1) DK2838920T3 (es)
DO (1) DOP2014000234A (es)
EA (1) EA029185B1 (es)
EC (1) ECSP14023405A (es)
ES (2) ES2621917T3 (es)
GT (1) GT201400217A (es)
HK (1) HK1201862A1 (es)
HR (1) HRP20170468T1 (es)
HU (1) HUE032153T2 (es)
IL (1) IL234965B (es)
IN (1) IN2014MN01876A (es)
LT (1) LT2838920T (es)
ME (1) ME02596B (es)
MX (1) MX367460B (es)
MY (1) MY173282A (es)
NZ (1) NZ630865A (es)
PE (1) PE20142147A1 (es)
PH (1) PH12014502333A1 (es)
PL (1) PL2838920T3 (es)
PT (1) PT2838920T (es)
RS (1) RS55729B1 (es)
SG (1) SG11201406726PA (es)
SI (1) SI2838920T1 (es)
TW (1) TWI585103B (es)
WO (1) WO2013158577A1 (es)
ZA (1) ZA201407272B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗tnf-抗il-17雙特異性抗體
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
JP6505689B2 (ja) * 2013-11-19 2019-04-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. ヒト化b細胞活性化因子遺伝子を有する非ヒト動物
EA033604B1 (ru) 2014-01-31 2019-11-08 Boehringer Ingelheim Int Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
BR112018001255A2 (pt) 2015-07-23 2018-09-11 Boehringer Ingelheim International Gmbh composto direcionado à il-23a e fator de ativação de células b (baff) e seus usos
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
EP3735272A4 (en) * 2018-01-05 2021-09-22 Biograph 55, Inc. COMPOSITIONS AND METHODS FOR IMMUNO CANCEROTHERAPY
WO2022258045A1 (zh) * 2021-06-11 2022-12-15 山东先声生物制药有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
WO2024140930A1 (en) * 2022-12-28 2024-07-04 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
MY169746A (en) * 2005-08-19 2019-05-14 Abbvie Inc Dual variable domain immunoglobulin and uses thereof
PT1963368E (pt) 2005-12-13 2012-09-14 Lilly Co Eli Anticorpos anti-il-17
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
CN104220455A (zh) 2014-12-17
EP2838920A1 (en) 2015-02-25
CA2869148C (en) 2017-06-20
AU2013249546B2 (en) 2017-10-26
SI2838920T1 (sl) 2017-03-31
CY1118824T1 (el) 2018-01-10
IL234965B (en) 2018-04-30
ES2789474T3 (es) 2020-10-26
US20160251430A1 (en) 2016-09-01
ZA201407272B (en) 2016-11-30
EA029185B1 (ru) 2018-02-28
TWI585103B (zh) 2017-06-01
US9708402B2 (en) 2017-07-18
CL2014002616A1 (es) 2015-01-30
AR090626A1 (es) 2014-11-26
ES2621917T3 (es) 2017-07-05
EP3192809A1 (en) 2017-07-19
PL2838920T3 (pl) 2017-07-31
PH12014502333B1 (en) 2014-12-22
HK1201862A1 (en) 2015-09-11
PH12014502333A1 (en) 2014-12-22
CR20140466A (es) 2014-11-13
MY173282A (en) 2020-01-10
KR20140135830A (ko) 2014-11-26
EA201491622A1 (ru) 2015-01-30
EP3192809B1 (en) 2020-04-15
GT201400217A (es) 2015-06-02
CN104220455B (zh) 2017-04-26
BR112014025649A2 (pt) 2017-07-04
PT2838920T (pt) 2017-05-03
MX2014012692A (es) 2015-01-22
AP2014008002A0 (en) 2014-10-31
PE20142147A1 (es) 2014-12-13
US20130280256A1 (en) 2013-10-24
EP2838920B1 (en) 2017-02-01
ECSP14023405A (es) 2015-09-30
SG11201406726PA (en) 2014-11-27
LT2838920T (lt) 2017-05-25
JP6216772B2 (ja) 2017-10-18
CA2869148A1 (en) 2013-10-24
US9359448B2 (en) 2016-06-07
CO7160039A2 (es) 2015-01-15
NZ630865A (en) 2016-02-26
KR101673735B1 (ko) 2016-11-07
DK2838920T3 (en) 2017-04-18
HRP20170468T1 (hr) 2017-06-02
HUE032153T2 (en) 2017-09-28
JP2015514423A (ja) 2015-05-21
DOP2014000234A (es) 2014-11-30
WO2013158577A1 (en) 2013-10-24
IN2014MN01876A (es) 2015-07-03
TW201402607A (zh) 2014-01-16
AU2013249546A1 (en) 2014-09-25
RS55729B1 (sr) 2017-07-31
ME02596B (me) 2017-06-20

Similar Documents

Publication Publication Date Title
MX367460B (es) Anticuerpos biespecificos anti-baff-anti-il-17.
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
PH12015501994A1 (en) Antibodies that bind il-23
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
EP4036240A3 (en) Transduction buffer
PH12015500294A1 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
EA035160B9 (ru) Антитела к st2 и их применение
EP4403570A3 (en) Anti-il-33 antibodies and uses thereof
MX2016006101A (es) Agente ligante de la il-17a y usos del mismo.
EA201491471A1 (ru) Состав, содержащий антитело против ил-17
MY158481A (en) Compositions and methods for treating inflammatory disorders
EP3573658A4 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS
BR112017011961A2 (pt) composições de polímero de polietileno de baixa névoa
EP4023674A3 (en) Anti-il-22r antibodies
MY174711A (en) Novel anti-fc-gamma receptor iib antibodies and uses thereof
EA201591334A1 (ru) Покрывающие композиции и способы применения
TN2014000413A1 (en) Anti-baff-anti-il-17 bispecific antibodies
WO2014201400A3 (en) Anti-factor viii antibodies or uses thereof
TH1401006266A (th) แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี
WO2014113431A3 (en) Methods and compositions for targeting immunoglobulins
UA113080C2 (xx) Біспецифічне антитіло, яке специфічно зв'язується з il17 та baff

Legal Events

Date Code Title Description
FG Grant or registration